| Pertuzumab | Genentech, Inc. | ||
| 420 mg / 14 mL ; Vial ; Single - Use |
More Than $1000 mn
|
||
| None |
Less Than 5
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| None | |||
|
No
| |||
| Perjeta | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | Patent 32 | Patent 33 | Patent 34 | Patent 35 | Patent 36 | Patent 37 | Patent 38 | Patent 39 | Patent 40 | Patent 41 | Patent 42 | Patent 43 | Patent 44 | Patent 45 | Patent 46 | Patent 47 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******** ******* ******* | ******* | ******* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | ******* | ******* | ******* | ******* | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | ******* | *** ********* | ******* | *** ********* | ******* | ******* | *** ********* | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | ******* | ******* | *** ********* | *** ********* | ******* | ******* | *** ********* |
| ****** ** ******* ***** ********** ******** | **** ******* ************ **** ************ *** ******* *** *********** ********** | ********* ** ********** ****** ****** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | **** ******* ************ **** ************ *** ******* *** *********** ********** | ********** ** ******** ** *********-**** **** ******* ***** | ****** *** *** ************ ** ********** | ******** ********* ** ****-******** ****** ****** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ****** ** ******* ***** ********** ******** | ************** ************ | *********** ********** ******** **** ***** ** ****** ** ** **** *** ****** ******** ******* | *********** ********** ******** **** ***** ** ****** ** ** **** *** ****** ******** ******* | ******** ********* ** ****-******** ****** ****** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ********* ** ********** ****** ****** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ******** ********* ** ****-******** ****** ****** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ********** ** ******** ** *********-**** **** ******* ***** | *********** ********** ******** **** ***** ** ****** ** ** **** *** ****** ******** ******* | ******** ********* ** ****-******** ****** ****** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ********** ******** *** ********** ******* | ********** ** ********* **** ********* ****** *********** ********** ** ************ | ***** ****** ** *** ********** | ********* ****-***** ********** *** ********* **** ****-***** ********** | ******** ************ | ***** ****** ** *** ********** | ********** ** ******** ** *********-**** **** ******* ***** | ********** ** ********* **** ********* ****** *********** ********** ** ************ | *********** ********** ******** **** ***** ** ****** ** ** **** *** ****** ******** ******* | ****** ** ******** ****** **** * ************** *********** ********** * **** ******** | *********** ********** ******** **** ***** ** ****** ** ** **** *** ****** ******** ******* | ************** ************ | ******* *** ***** ************ *** ***** ************ ****** | ****** *** *** ************ ** ********** | ********** ** ******** ** *********-**** **** ******* ***** | ********** ******** *** ********** ******* | ********** ******** *** ********** ******* | **** ******* ************ **** ************ *** ******* *** *********** ********** | ******* ******** ******** *********** *** ****** *** ********* ** | **** ******* ************ **** ************ *** ******* *** *********** ********** | ******* *** ***** ************ *** ***** ************ ****** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******** ******* ******* | ******* | ******** | ******* *** **** *** **** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|